{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:24:07Z","timestamp":1791498247092,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"24","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41388-018-0126-2","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T03:23:10Z","timestamp":1520220190000},"page":"3216-3228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer"],"prefix":"10.1038","volume":"37","author":[{"given":"Vikash","family":"Reebye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6375-8714","authenticated-orcid":false,"given":"Kai-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheba","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3426-2274","authenticated-orcid":false,"given":"Pedro","family":"Cutilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Ciriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinelopi","family":"Andrikakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Voutila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pal","family":"Saetrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Mintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Reccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Kostomitsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Blakey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagy A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"126_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJMra1504367","volume":"375","author":"PS Ge","year":"2016","unstructured":"Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375:767\u201377.","journal-title":"N Engl J Med"},{"key":"126_CR2","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1002\/hep.28812","volume":"64","author":"AM Allen","year":"2016","unstructured":"Allen AM, Kim WR, Moriarty JP, Shah ND, Larson JJ, Kamath PS. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology. 2016;64:2165\u201372.","journal-title":"Hepatology"},{"key":"126_CR3","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/hep.23594","volume":"51","author":"BQ Starley","year":"2010","unstructured":"Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820\u201332.","journal-title":"Hepatology"},{"key":"126_CR4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547\u201354.","journal-title":"Hepatology"},{"key":"126_CR5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/wrna.90","volume":"2","author":"V Portnoy","year":"2011","unstructured":"Portnoy V, Huang V, Place RF, Li LC. Small RNA and transcriptional upregulation. WIREs RNA. 2011;2:748\u201360.","journal-title":"WIREs RNA"},{"key":"126_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/cr.2016.22","volume":"26","author":"V Portnoy","year":"2016","unstructured":"Portnoy V, Lin SHS, Li KH, Burlingame A, Hu Z-H, Li H, et al. saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription. Cell Res. 2016;26:320\u201335.","journal-title":"Cell Res"},{"key":"126_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1872-034X.2007.00074.x","volume":"37","author":"S Mei","year":"2007","unstructured":"Mei S, Wang X, Zhang J, Qian J, Ji J. In vivo transfection of C\/EBP-alpha gene could ameliorate CCL(4)-induced hepatic fibrosis in mice. Hepatol Res. 2007;37:531\u20139.","journal-title":"Hepatol Res"},{"key":"126_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10495-012-0700-y","volume":"17","author":"LL Tao","year":"2012","unstructured":"Tao L-L, Cheng Y-Y, Ding D, Mei S, Xu J-W, Yu J, et al. C\/EBP-\u03b1 ameliorates CCl(4)-induced liver fibrosis in mice through promoting apoptosis of hepatic stellate cells with little apoptotic effect on hepatocytes in vitro and in vivo. Apoptosis. 2012;17:492\u2013502.","journal-title":"Apoptosis"},{"key":"126_CR9","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1074\/jbc.M113.526780","volume":"289","author":"IH Hong","year":"2014","unstructured":"Hong I-H, Lewis K, Iakova P, Jin J, Sullivan E, Jawanmardi N, et al. Age-associated change of C\/EBP family proteins causes severe liver injury and acceleration of liver proliferation after CCl4 treatments. J Biol Chem. 2014;289:1106\u20138.","journal-title":"J Biol Chem"},{"key":"126_CR10","doi-asserted-by":"publisher","first-page":"10330","DOI":"10.1158\/0008-5472.CAN-04-4486","volume":"65","author":"HT Ee","year":"2005","unstructured":"Ee HT, Shing CH, Mirtha L, Esther W, Sathivel P, Aileen W. et al. CAAT\/enhancer binding protein alpha knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma. Cancer Res.2005;65:10330\u20137.","journal-title":"Cancer Res."},{"key":"126_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.dld.2013.03.013","volume":"45","author":"YC Shi","year":"2013","unstructured":"Shi Y-C, Zhao H, Yin C, Zeng X, Zhang Q, Xu W-P, et al. C\/EBP\u03b1 inhibits hepatocellular carcinoma by reducing Notch3\/Hes1\/p27 cascades. Dig Liver Dis. 2013;45:844\u201351.","journal-title":"Dig Liver Dis"},{"key":"126_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/hep.26669","volume":"59","author":"V Reebye","year":"2014","unstructured":"Reebye V, S\u00e6trom P, Mintz PJ, Huang K-W, Swiderski P, Peng L, et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology. 2014;59:216\u201327.","journal-title":"Hepatology"},{"issue":"12","key":"126_CR13","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.ymthe.2017.07.018","volume":"25","author":"Jon Voutila","year":"2017","unstructured":"Voutila J, Reebye V, Roberts TC, Protopapa P, Andrikakou P, Blakey DC et al. Development and mechanism of small activating RNA targeting CEBPA, a novel therapeutic in clinical trials for liver cancer. Mol Ther 2017;25:2705\u201314.","journal-title":"Molecular Therapy"},{"key":"126_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00280-014-2476-y","volume":"74","author":"WV Rodrigueza","year":"2014","unstructured":"Rodrigueza WV, Woolliscroft MJ, Ebrahim A-S, Forgey R, McGovren PJ, Endert G, et al. Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide. Cancer Chemother Pharmacol. 2014;74:151\u201366.","journal-title":"Cancer Chemother Pharmacol"},{"key":"126_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/hep.26669","volume":"59","author":"V Reebye","year":"2014","unstructured":"Reebye V, S\u00e6trom P, Mintz PJ, Huang K-W, Swiderski P, Peng L, et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology. 2014;59:216\u201327.","journal-title":"Hepatology"},{"key":"126_CR16","first-page":"3176","volume":"61","author":"L Xu","year":"2001","unstructured":"Xu L, Hui L, Wang S, Gong J, Jin Y, Wang Y, et al. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res. 2001;61:3176\u201381.","journal-title":"Cancer Res"},{"key":"126_CR17","first-page":"351","volume":"23","author":"M Tomizawa","year":"2003","unstructured":"Tomizawa M, Watanabe K, Saisho H, Nakagawara A, Tagawa M. Down-regulated expression of the CCAAT\/enhancer binding protein alpha and beta genes in human hepatocellular carcinoma: a possible prognostic marker. Anticancer Res. 2003;23:351\u20134.","journal-title":"Anticancer Res"},{"key":"126_CR18","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1053\/j.gastro.2010.03.051","volume":"139","author":"GD Lu","year":"2010","unstructured":"Lu G-D, Leung CH-W, Yan B, Tan CM-Y, Low SY, Aung MO, et al. C\/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation. Gastroenterology. 2010;139:632\u201343.","journal-title":"Gastroenterology"},{"key":"126_CR19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.tcb.2007.07.004","volume":"17","author":"C Nerlov","year":"2007","unstructured":"Nerlov C. The C\/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol. 2007;17:318\u201324.","journal-title":"Trends Cell Biol"},{"key":"126_CR20","doi-asserted-by":"publisher","first-page":"44740","DOI":"10.1074\/jbc.M405177200","volume":"279","author":"Y Inoue","year":"2004","unstructured":"Inoue Y, Inoue J, Lambert G, Yim SH, Gonzalez FJ. Disruption of hepatic C\/EBPalpha results in impaired glucose tolerance and age-dependent hepatosteatosis. J Biol Chem. 2004;279:44740\u20138.","journal-title":"J Biol Chem"},{"key":"126_CR21","first-page":"1063","volume":"56","author":"PJ Watkins","year":"1996","unstructured":"Watkins PJ, Condreay JP, Huber BE, Jacobs SJ, Adams DJ. Impaired proliferation and tumorigenicity induced by CCAAT\/enhancer-binding protein. Cancer Res. 1996;56:1063\u20137.","journal-title":"Cancer Res"},{"key":"126_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fgene.2012.00120","volume":"3","author":"AG Bader","year":"2012","unstructured":"Bader AG. miR-34\u2013a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120.","journal-title":"Front Genet"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0126-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0126-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0126-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:10:22Z","timestamp":1684602622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0126-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":22,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["126"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0126-2","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"2 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"J.V., S.C., D.B., and R.H. are current or former employees of MiNA Therapeutics Limited. V.R., P.J.M., K.W.-H., P.S., J.J.R., and N.H. own stock in MiNA (Holdings) Limited. All remaining authors have no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}